Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.1234
Bottom line from this bounded source set
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.1234
Reviewed study record
Phase 2 obesity trial
Design
A randomized, double-blind, placebo-controlled dose-finding Phase 2 trial assessed body-weight change over 46 weeks.1
Population
The trial treated 386 adults with overweight or obesity without diabetes across 43 centers in 12 countries.1
Outcomes reported
Reported mean body-weight change ranged from -6.2% to -14.9% across planned survodutide groups and was -2.8% with placebo. About 60% completed the treatment period, and gastrointestinal events were more frequent with survodutide.1
Limitations
The sponsor-funded trial was Phase 2, had substantial treatment-period attrition, and Crossref registers a publisher erratum with two upstream dates for the same notice. Crossref metadata alone does not describe the corrected wording.1
Reviewed study record
Phase 2 MASH and fibrosis trial
Design
A randomized, placebo-controlled Phase 2 trial assessed histologic improvement in steatohepatitis without worsening fibrosis over 48 weeks.2
Population
The trial treated 293 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and fibrosis stages F1 through F3.2
Outcomes reported
Improvement in steatohepatitis without worsening fibrosis was reported in 43% to 62% across survodutide groups and 14% with placebo. Improvement in fibrosis by at least one stage was reported in 34% to 36% and 22%, respectively.2
Limitations
The sponsor-funded, 48-week Phase 2 trial was not designed to establish long-term liver-related clinical outcomes or uncommon harms, and the fibrosis result was a secondary endpoint.2
Reviewed study record
SYNCHRONIZE-1: phase 3 obesity study
Design
A blinded randomized placebo-controlled trial assessed percentage weight change and at least 5% weight reduction at 76 weeks, under NCT06066515.3
Population
The report describes 725 adults with obesity or overweight with a related complication, excluding diabetes.3
Outcomes reported
The treatment-regimen analysis reported mean weight changes of −12.2% and −13.0% in the active groups versus −5.4% with placebo. Gastrointestinal events occurred in 80.9% and 89.7% of active groups versus 47.9% with placebo.3
Limitations
The analysis includes treatment discontinuation and other specified intercurrent events. Weight reduction does not itself establish fewer cardiovascular events or other long-term complications. No deaths were reported.3
Reviewed study record
SYNCHRONIZE-MASLD: liver-fat and weight endpoints
Design
A blinded randomized placebo-controlled phase 3 study assessed MRI-measured liver-fat reduction and weight change at 48 weeks.4
Population
The abstract describes 216 treated adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease.4
Outcomes reported
Under the treatment-regimen analysis, 68.5% with survodutide and 28.6% with placebo reached at least 30% liver-fat reduction. Mean weight changes were −8.7% and −1.4%, respectively. Gastrointestinal adverse events were common.4
Limitations
The larger estimates in the efficacy analysis answer a different question from the treatment-regimen analysis. MRI liver fat is not a clinical liver-event outcome. A linked publisher correction is recorded with this source; follow-up was short and recruitment was limited to the United States and Spain.4
Publication update registered by CrossrefErratum ↗ · publisher metadata · December 17, 2025 and February 1, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2401755. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2600751. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Publication update registered by CrossrefCorrection ↗ · publisher metadata · August 25, 2026. Crossref metadata identifies the notice but does not by itself explain what wording changed.